Metabolische Chirurgie

Christine Stroh; Daniel Luderer

doi:10.1055/a-1652-4605

Allgemein- und Viszeralchirurgie up2date, Table of Contents

Allgemein- und Viszeralchirurgie up2date 2022; 16(04): 293-309
DOI: 10.1055/a-1652-4605

Bariatrische und metabolische Chirurgie

Metabolische Chirurgie

Christine Stroh

,

Daniel Luderer

Abstract

All articles of this category

Die metabolische Chirurgie ist aktuell die effektivste Therapie zur Behandlung der morbiden Adipositas und der assoziierten Begleiterkrankungen. Der Beitrag stellt die Operationsverfahren und deren Stellenwert vor.

Schlüsselwörter

Adipositaschirurgie - metabolische Chirurgie - Diabetes mellitus - mikrovaskuläre Komplikationen - makrovaskuläre Komplikationen - nicht alkoholische Fettlebererkrankung

Full Text

References

Literatur
1 Hung S, Chen C, Chin W. et al. The long-term risk of cardiovascular events in patients following bariatric surgery compared to a non-surgical population with obesity and the general population: a comprehensive national cohort study. Langenbeckʼs Arch Surg 2021; 406: 189-196
2 Carlsson L, Sjöholm K, Jacobson P. et al. Life expectancy after bariatric surgery in the Swedish Obese Subject Study. N Engl J Med 2020; 383: 1535
3 Schauer PR, Bhatt DL, Kirwan JP. et al. Bariatric surgery versus intensive medical therapy for diabetes–5-year outcomes. N Engl J Med 2017; 376: 641-651
4 Rubino F, Nathan DM, Eckel RH. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by International Diabetes Organizations. Diabetes Care 2016; 39: 861-877
5 Adams LA, Waters OR, Knuiman MW. et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861-867
6 Colquitt JL, Pickett K, Loveman E. et al. Surgery for weight loss in adults. Cochrane Database Syst Rev 2014; (08) CD003641
7 Yan Y, Sha Y, Yao G. et al. Roux-en-Y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine 2016; 95: e3462
8 Deutsche Adipositas-Gesellschaft e.V. (DAG). et al. S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. 2018. Version 2.3. AWMF-Register Nr. 088–001. Im Internet (Stand: 16.06.2022): https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf
9 Aminian A, Al-Kurd A, Wilson R. et al. Association of Bariatric Surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 2021; 326: 2031-2042
10 Lassailly G, Caiazzo R, Ntandja-Wandji LC. et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 2020; 159: 1290-1301.e5
11 Stroh C, Hohmann U, Manger T. Prinzipien der Adipositaschirurgie. Internist Prax 2015; 55: 737-746
12 Thaher O, Hukauf M, Stroh C. Propensity score matching sleeve gastrectomy vs. gastric bypass with 5 years of follow-up. Obes Surg 2021; 31: 5156-5165
13 Peterli R, Wolnerhanssen BK, Peters T. et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic roux-en-y-gastric bypass on weight loss in patients with morbid obesity: The SM-BOSS Randomized Clinical Trial. JAMA 2018; 319: 255-265
14 Mingrone G, Panunzi S, De Gaetano A. et al. Bariatric surgery versus conventional therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585
15 Mingrone G, Panunzi S, de Gaetano A. et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow up on an open-label, single-centre, randomised controlled trial. Lancet 2015; 386: 964-973
16 Salminen P, Helmiö M, Ovaska J. et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity. The SLEEVEPASS randomized clinical trial. JAMA 2018; 319: 241-254
17 Wölnerhanssen B, Peterli R, Hurme S. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS). Br J Surg 2021; 108: 49-57
18 Robert M, Espalieu P, Pelascini E. et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomized, open-label, non-inferiority trial. Lancet 2019; 393: 1299-1309
19 Sjöström L, Lindroos A, Peltonen P. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693
20 Biertho L, Lebel S, Marceau S. et al. Biliopancreatic diversion with duodenal switch: Surgical Technique and operative care. Surg Clin North Am 2016; 96: 815-826
21 Bueter M, le Roux CW. Gastrointestinal hormones, energy balance and bariatric surgery. Int J Obes (Lond) 2011; 35 Suppl 3: S35-S39
22 Buhmann H, le Roux CW, Bueter M. The gut-brain axis in obesity. Best Pract Res Clin Gastroenterol 2014; 28: 559-571
23 Moreno-Arciniegas A, Falckenheiner-Soria J, Bancalero-De Los Reyes J. et al. The main participation of the enterohormone GLP-1 after bariatric surgery. Minerva Chir 2019; 74: 7-13
24 Steinert RE, Feinle-Bisset C, Asarian L. et al. Ghrelin, CCK, GLP-1, and PYY (3-36): Secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 2017; 97: 411-463
25 Steinert RE, Rehman A, Souto Lima EJ. et al. Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients – a pilot study. PloS One 2020; 15: e0236936
26 Albaugh VL, Banan B, Antoun J. et al. Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery. Gastroenterology 2019; 156: 1041-1051.e4
27 Bozadjieva N, Heppner K, Seeley R. Targeting FXR and FGF19 to treat metabolic diseases – lessons learned from bariatric surgery. Diabetes 2018; 67: 1720
28 Debedat J, Sokovska N, Couzpaye M. et al. Long-term relapse of type 2 diabetes after Roux-en-Y gastric bypass: prediction and clinical relevance. Diabetes Care 2018; 41: 2086-2095
29 Thereux J, Lesuffleur T, Czernichow S. et al. Association between bariatric surgery and rates of continuation, discontinuation, or initiation of antidiabetes treatment 6 years later. JAMA Surg 2018; 153: 526-533
30 Fischer D, Johnson E, Hanreuse S. et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA 2018; 320: 1570-1582
31 OʼBrien R, Johnson E, Haneuse S. et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care. Ann Int Med 2018; 169: 300-310
32 Billeter A, Scheurlen K, Probst P. et al. Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. Br J Surg 2018; 105: 168-181
33 Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008; 34: 634-637
34 Schauer DP, Feigelson HS, Koebnick C. et al. Bariatric surgery and the risk of cancer in a large multisite cohort. Ann Surg 2019; 269: 95-101
35 Feigelson HS, Caan B, Weinmann S. et al. Bariatric Surgery is associated with reduced risk of breast cancer in both premenopausal and postmenopausal women. Ann Surg 2020; 272: 1053-1059
36 Bailly L, Fabre R, Pradier C. et al. Colorectal cancer risk following bariatric surgery in a nationwide study of French individuals with obesity. JAMA Surg 2020; 155: 395-402
37 Hussan H, Patel A, Le Roux M. et al. Rising incidence of colorectal cancer in young adults corresponds with increasing surgical resections in obese patients. Clin Transl Gastroenterol 2020; 11: e00160
38 Stroh C, Meyer F, Manger T. Nutritive Defizite und Supplementation nach metabolischer Chirurgie. Chirurg 2016; 87: 762-767
39 Almeanazel O, Alanazi F, Alsarra I. et al. Nanotechnology as a tool to overcome the bariatric surgery malabsorption. Saudi Pharm J 2020; 28: 565-573
40 Anvari S, Lee Y, Lam M. et al. The effect of bariatric surgery on oral antibiotic absorption: a systematic review. Obes Surg 2020; 30: 2883-2892
41 Carlsson LMS, Sjöholm K, Jacobson P. et al. Life Expectancy after bariatric surgery in the Swedish Obese Subjects Study. N Engl J Med 2020; 383: 1535-1543
42 Stroh C, Croner R. 16. Studientreffen des GBSR. CHAZ 2020; 10: 537-539